Tirzepatide may have direct protective effects on various tissues that play a role in MASLD pathology.40,41 Furthermore, glucagon and GIP have direct effects on hepatic fatty acid β-oxidation and lipogenesis, contributing to decreased LFC. Here, GIP is linked to metabolic dysfunction-associated steatotic liver disease.